Article Information
History
- August 23, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Phillip L.R. Nicolson, MD, PhD1,2,*,
- Samantha J. Montague, PhD1,
- Christopher W. Smith, PhD1,
- Clare S. Lodwick, MD3,
- Charlotte Stoneley, MSc4,
- Matthew Roberts, MSc4,
- Steve P. Watson, PhD1,
- Gillian C. Lowe, MD PhD2 and
- William A. Lester, MD, PhD2
- 1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
- 2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
- 3Department of Haematology, Worcester Acute Hospitals NHS Trust, Worcester WR5 1DD, UK
- 4Department of Blood Sciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK
- ↵*Corresponding authors:
Phillip L.R. Nicolson, email: p.nicolson{at}bham.ac.uk, Steve P Watson, email: s.p.watson{at}bham.ac.uk
Posted August 23, 2021.
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination
